View in EDS HTML Full Text PDF Full Text

Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors.

Saved in:
Bibliographic Details
Title: Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors.
Authors: Italiano A; Département d'oncologie médicale - Sarcomes, Centre Régional de Lutte Contre le Cancer (CLCC) Institut Bergonié, Bordeaux, France., García Manrique T; Department of Medical Oncology, Hospital Universitario Virgen Macarena, Seville, Spain., Grande Pulido E; Servicio de Oncología Médica, MD Anderson Cancer Center, Madrid, Spain., Kerrigan K; Division of Medical Oncology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, United States., Fléchon A; Department of Medical Oncology, Centre Léon Bérard Centre Régional de Lutte Contre le Cancer, Lyon, France., Martínez Pérez J; Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain., Żurawski B; Department of Outpatient Chemotherapy, Centrum Onkologii Szpital im. prof. Franciszka Łukaszczyka w Bydgoszczy, Bydgoszcz, Poland., Furqan M; Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, United States., Juan-Vidal O; Medical Oncology Service, Hospital Universitari i Politècnic la Fe, Valencia, Spain., Vaishampayan U; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States., Fares C; Department of Medical Oncology, Virginia Piper Cancer Center, Allina Health Cancer Institute, Minneapolis, MN, United States., Fang B; Department of Medical Oncology, Astera Cancer Care, East Brunswick, NJ, United States., Vicuna B; Department of Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, United States., Greillier L; Multidisciplinary Oncology and Therapeutic Innovations Department, Centre d'Essais Précoces en Cancérologie de Marseille (CEPCM), Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France., Subbiah V; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Dong M; Gilead Sciences, Inc., Foster City, CA, United States., Song K; Gilead Sciences, Inc., Foster City, CA, United States., Zhang Y; Gilead Sciences, Inc., Foster City, CA, United States., Kim Y; Gilead Sciences, Inc., Foster City, CA, United States., Paz-Ares L; Department of Medical Oncology, Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Complutense University and Ciberonc, Madrid, Spain.
Source: Frontiers in oncology [Front Oncol] 2026 Apr 22; Vol. 16, pp. 1786385. Date of Electronic Publication: 2026 Apr 22 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42100424
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Italiano+A%22">Italiano A</searchLink>; Département d'oncologie médicale - Sarcomes, Centre Régional de Lutte Contre le Cancer (CLCC) Institut Bergonié, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22García+Manrique+T%22">García Manrique T</searchLink>; Department of Medical Oncology, Hospital Universitario Virgen Macarena, Seville, Spain.<br /><searchLink fieldCode="AU" term="%22Grande+Pulido+E%22">Grande Pulido E</searchLink>; Servicio de Oncología Médica, MD Anderson Cancer Center, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Kerrigan+K%22">Kerrigan K</searchLink>; Division of Medical Oncology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, United States.<br /><searchLink fieldCode="AU" term="%22Fléchon+A%22">Fléchon A</searchLink>; Department of Medical Oncology, Centre Léon Bérard Centre Régional de Lutte Contre le Cancer, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Martínez+Pérez+J%22">Martínez Pérez J</searchLink>; Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain.<br /><searchLink fieldCode="AU" term="%22Żurawski+B%22">Żurawski B</searchLink>; Department of Outpatient Chemotherapy, Centrum Onkologii Szpital im. prof. Franciszka Łukaszczyka w Bydgoszczy, Bydgoszcz, Poland.<br /><searchLink fieldCode="AU" term="%22Furqan+M%22">Furqan M</searchLink>; Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, United States.<br /><searchLink fieldCode="AU" term="%22Juan-Vidal+O%22">Juan-Vidal O</searchLink>; Medical Oncology Service, Hospital Universitari i Politècnic la Fe, Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Vaishampayan+U%22">Vaishampayan U</searchLink>; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.<br /><searchLink fieldCode="AU" term="%22Fares+C%22">Fares C</searchLink>; Department of Medical Oncology, Virginia Piper Cancer Center, Allina Health Cancer Institute, Minneapolis, MN, United States.<br /><searchLink fieldCode="AU" term="%22Fang+B%22">Fang B</searchLink>; Department of Medical Oncology, Astera Cancer Care, East Brunswick, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Vicuna+B%22">Vicuna B</searchLink>; Department of Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, United States.<br /><searchLink fieldCode="AU" term="%22Greillier+L%22">Greillier L</searchLink>; Multidisciplinary Oncology and Therapeutic Innovations Department, Centre d'Essais Précoces en Cancérologie de Marseille (CEPCM), Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.<br /><searchLink fieldCode="AU" term="%22Subbiah+V%22">Subbiah V</searchLink>; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.<br /><searchLink fieldCode="AU" term="%22Dong+M%22">Dong M</searchLink>; Gilead Sciences, Inc., Foster City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Song+K%22">Song K</searchLink>; Gilead Sciences, Inc., Foster City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Zhang+Y%22">Zhang Y</searchLink>; Gilead Sciences, Inc., Foster City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Kim+Y%22">Kim Y</searchLink>; Gilead Sciences, Inc., Foster City, CA, United States.<br /><searchLink fieldCode="AU" term="%22Paz-Ares+L%22">Paz-Ares L</searchLink>; Department of Medical Oncology, Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Complutense University and Ciberonc, Madrid, Spain.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2026 Apr 22; Vol. 16, pp. 1786385. <i>Date of Electronic Publication: </i>2026 Apr 22 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42100424
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2026.1786385
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1786385
    Titles:
      – TitleFull: Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Italiano A
      – PersonEntity:
          Name:
            NameFull: García Manrique T
      – PersonEntity:
          Name:
            NameFull: Grande Pulido E
      – PersonEntity:
          Name:
            NameFull: Kerrigan K
      – PersonEntity:
          Name:
            NameFull: Fléchon A
      – PersonEntity:
          Name:
            NameFull: Martínez Pérez J
      – PersonEntity:
          Name:
            NameFull: Żurawski B
      – PersonEntity:
          Name:
            NameFull: Furqan M
      – PersonEntity:
          Name:
            NameFull: Juan-Vidal O
      – PersonEntity:
          Name:
            NameFull: Vaishampayan U
      – PersonEntity:
          Name:
            NameFull: Fares C
      – PersonEntity:
          Name:
            NameFull: Fang B
      – PersonEntity:
          Name:
            NameFull: Vicuna B
      – PersonEntity:
          Name:
            NameFull: Greillier L
      – PersonEntity:
          Name:
            NameFull: Subbiah V
      – PersonEntity:
          Name:
            NameFull: Dong M
      – PersonEntity:
          Name:
            NameFull: Song K
      – PersonEntity:
          Name:
            NameFull: Zhang Y
      – PersonEntity:
          Name:
            NameFull: Kim Y
      – PersonEntity:
          Name:
            NameFull: Paz-Ares L
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 22
              M: 04
              Text: 2026 Apr 22
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 16
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1